Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Acute myeloid leukemia cost-effectiveness of therapy

Introduction

Overview

Overview

A limited number of cost-effective studies have been done. For the acute promyelocytic leukemia subtype of acute myeloid leukemia, these studies showed that all-trans retinoic acid-based therapy is more cost-effective than chemotherapy.

Cost-effectiveness of therapy

Cost-effectiveness of therapy

A limited number of cost-effectiveness studies have been performed in acute myeloid leukemia. One comprehensive cost-effective analysis studied the costs of therapy.

  • The combination of all-trans retinoic acid plus idarubicin was more cost-effective than the combination of all-trans retinoic acid plus cytarabine plus additional chemotherapy.[1]
    • The incremental cost-effective ratio for all-trans retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.[1]
  • The combination of all-trans retinoic acid plus arsenic trioxide was more cost-effective than all-trans retinoic acid plus idarubicin.[1]
    • The incremental cost-effective ratio for all-trans retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.[1]
References

References

  1. ↑ 1.0 1.1 1.2 1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). “Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States”. Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]